MDT-AP-1146
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 39.96
- os_event
- true
- age_years
- 9
- sex
- M
- new_clusters
- C4
- umap1_2d
- 3.020505741
- umap2_2d
- 5.19857843
- umap1_3d
- 1.009705476
- umap2_3d
- -0.328775989
- umap3_3d
- -2.193061477
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.500
- G2M_CHECKPOINT+0.420
- MYC_TARGETS_V1+0.370
- DNA_REPAIR+0.360
- MYC_TARGETS_V2+0.340
- SPERMATOGENESIS+0.220
- MITOTIC_SPINDLE+0.190
- MTORC1_SIGNALING+0.190
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.180
- UV_RESPONSE_UP+0.140
Top 10 suppressed
- NOTCH_SIGNALING-0.390
- KRAS_SIGNALING_DN-0.330
- APICAL_SURFACE-0.250
- MYOGENESIS-0.250
- ANGIOGENESIS-0.240
- HYPOXIA-0.220
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.210
- UV_RESPONSE_DN-0.200
- ESTROGEN_RESPONSE_EARLY-0.180
- IL6_JAK_STAT3_SIGNALING-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-44-7669-01A-21R-2066-07 | — | cohortA3 | 0.837 |
| 2 | TCGA-ZF-A9RN-01A-11R-A42T-07 | — | — | 0.837 |
| 3 | 1c3eaf9a-ffda-4c6d-bffb-2610a37ab837 | — | — | 0.827 |
| 4 | 45a758dc-af09-48d3-8cd2-15232593f385 | — | — | 0.821 |
| 5 | MDT-AP-0202 | Med | Medulloblastoma | 0.817 |
| 6 | BS_8GW1TMV2 | medulloblastoma | — | 0.814 |
| 7 | SRR23303750 | — | — | 0.810 |
| 8 | 57ab4aef-e740-4494-b0b5-3b008f9d446f | — | — | 0.808 |
| 9 | BS_A0DYVX9J | high-grade glioma | — | 0.807 |
| 10 | TCGA-66-2787-01A-01R-0980-07 | — | cohortSQ2 | 0.784 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.420 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.370 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.360 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.340 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.220 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.190 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.190 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.180 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.140 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.120 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.120 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.120 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.090 | Cobimetinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.080 | Remibrutinib | — uncovered |
| PEROXISOME | 0.070 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.060 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.060 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.040 | Idelalisib | — uncovered |
| APOPTOSIS | 0.020 | Idelalisib | — uncovered |